Talia H Swartz, MD, PhD
img_Talia H Swartz
ASSOCIATE PROFESSOR | Medicine, Infectious Diseases
Are you a patient?
Infectious Disease, Internal Medicine
Research Topics
Cellular Immunity, Cytokines, HIV/AIDS, Imaging, Immunology, Infectious Disease, Inflammation, Membrane Proteins/Channels, Membranes, Microbiology, Microglia, Mucosal Immunology, Opioid/Cannabinoid Receptors, T Cells, Translational Research, Transporters, Virulence Genes, Viruses and Virology
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Genetics and Genomic Sciences [GGS], Immunology [IMM], Microbiology [MIC], Neuroscience [NEU]
Dissecting the mechanisms of HIV-1 infection and inflammatory signaling in human lymphoid tissue
Purinergic receptors and downstream inflammasome signaling mediators are important contributors to HIV-1 entry and in driving inflammation. Preliminary data indicate that inhibitors of purinergic signaling reduce both HIV-1 infection and inflammatory cytokine signaling. Our goal is to elucidate the role of HIV-1 in mediating inflammatory signaling in lymphoid tissue.
Functional Assessment of anti-Env and inflammatory markers during delayed FTR-mediated virologic control
The goal of this study is to test the role of enhanced antibody responses in the delayed virologic control observed in Fostemsavir treated patients who have multidrug resistant HIV.
Elucidating the mechanisms of cannabinoids on HIV-1 infection and inflammasome activation
Recent evidence has suggested an important role of the NLRP3 inflammasome as a driver of inflammation. Cannabinoids have been shown to reduce inflammasome activity. What remains unknown is the effect that cannabinoids have on HIV-stimulated NLRP3 inflammasome activity. Our goal is to elucidate the role of cannabinoids in modulating HIV-inflammasome signaling in lymphoid tissue.
Building a diverse and robust physician scientist pipeline
The lack of diversity in gender, race/ethnicity, of the physician scientist pipeline threatens the ability of the biomedical workforce to serve the needs of our patients. There is a critical need for us to expand the diversity of the physician scientist workforce through recruitment, admissions, and retention efforts.
Modeling HIV microglia-association infection and inflammation in a chimeric mouse brain
To better understand how HIV affects the brain in the era of combination antiretroviral therapy, and to improve current treatment options, we will study the cell susceptible to HIV infection human microglia, in the mouse brain. This includes novel experimental therapies of antiretrovirals combined with cannabinoid receptor-specific drugs that could lower the extent of inflammation and infection in the brain.

PhD, Mount Sinai School of Medicine

MD, Icahn School of Medicine at Mount Sinai

Residency, Internal Medicine, Mount Sinai Hospital

Fellowship, Infectious Disease, Mount Sinai Hospital


Junior Faculty Research Award

Infectious Diseases Society of New York



Infectious Diseases Society of America


Master Educator

Institute for Medical Education, Icahn School of Medicine at Mount Sinai


Distinguished Scholar Award

Icahn School of Medicine at Mount Sinai


Excellence in Teaching Award

Institute for Medical Education, Icahn School of Medicine at Mount Sinai


Edward J. Ronan Award

Student Council, Icahn School of Medicine at Mount Sinai


Translational Collaborative Research Development Award

Department of Medicine, Icahn School of Medicine at Mount Sinai


Junior Faculty Award

Faculty Council, Icahn School of Medicine at Mount Sinai


Alpha Omega Alpha Postgraduate Research Award

Lambda Chapter


Alpha Omega Alpha, Resident/Fellow Member

Lambda Chapter


House Staff Excellence in Teaching Award

Institute for Medical Education, Mount Sinai School of Medicine

Talia Swartz HIV Education Video
Mount Sinai Spotlight: HIV Research
2020 Distinguished Scholar Award - Dr. Talia Swartz
50th Anniversary: Dr. Talia Swartz Story
Understanding the mechanisms of HIV-1 as an inflammatory disease
View All Videos

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Swartz did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.